SeekingAlpha · Aug 13, 2026
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsRaffi Asadorian - Chief Financial OfficerVincent Angotti - CEO...
TL
NASDAQ · TLPH
Talphera, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.19
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 2:41 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 24.41M
- P/E ratio
- -3.63
- Dividend yield
- 0.00%
- 52-week range
- $0.69 – $1.50
- Volume
- 109.54K
- Avg. volume
- 385.05K
Price performance
TLPH price history
1M range · 20 trading sessions · Daily adjusted prices
TLPH closed at $1.19 after 20 trading sessions, down 5.56% for the selected period.
- Last close
- $1.19
- Period change
- -5.56%
- Period low
- $1.19
- Period high
- $1.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.19 | $1.215 | $1.17 | $1.19 | 109.54K |
| Aug 20, 2026 | $1.19 | $1.205 | $1.175 | $1.19 | 217.48K |
| Aug 19, 2026 | $1.21 | $1.23 | $1.18 | $1.19 | 558.76K |
| Aug 18, 2026 | $1.19 | $1.24 | $1.185 | $1.21 | 425.25K |
| Aug 17, 2026 | $1.24 | $1.27 | $1.18 | $1.20 | 346.98K |
| Aug 14, 2026 | $1.20 | $1.28 | $1.19 | $1.23 | 341.76K |
| Aug 13, 2026 | $1.34 | $1.36 | $1.11 | $1.21 | 1.57M |
| Aug 12, 2026 | $1.49 | $1.50 | $1.3201 | $1.40 | 497.73K |
| Aug 11, 2026 | $1.40 | $1.4999 | $1.38 | $1.47 | 366.16K |
| Aug 10, 2026 | $1.43 | $1.43 | $1.40 | $1.41 | 95.6K |
| Aug 7, 2026 | $1.44 | $1.47 | $1.41 | $1.43 | 199.63K |
| Aug 6, 2026 | $1.40 | $1.44 | $1.38 | $1.43 | 343.49K |
| Aug 5, 2026 | $1.37 | $1.43 | $1.35 | $1.35 | 170.3K |
| Aug 4, 2026 | $1.33 | $1.39 | $1.3286 | $1.36 | 123.03K |
| Aug 3, 2026 | $1.26 | $1.3399 | $1.26 | $1.33 | 121.33K |
| Jul 31, 2026 | $1.35 | $1.4089 | $1.28 | $1.28 | 197.35K |
| Jul 30, 2026 | $1.32 | $1.355 | $1.31 | $1.355 | 71.06K |
| Jul 29, 2026 | $1.29 | $1.35 | $1.26 | $1.31 | 132.94K |
| Jul 28, 2026 | $1.23 | $1.31 | $1.22 | $1.30 | 147.96K |
| Jul 27, 2026 | $1.35 | $1.35 | $1.25 | $1.26 | 389.84K |
Latest TLPH news
The latest Smart Investors Daily articles mentioning TLPH.
Stock researchCompany · Overview
TLPH research
Overview
Company profile and research snapshot.
Company profile
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | WestPark Capital | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Talphera Q2 EPS $(0.06) Beats $(0.07) Estimate
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per share from the same
Yahoo · Aug 5, 2026
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.
Benzinga · Jun 5, 2026
HC Wainwright & Co. Assumes Talphera at Buy, Announces Price Target of $3
HC Wainwright & Co. analyst Brandon Folkes assumes Talphera (NASDAQ:TLPH) with a Buy rating and announces Price Target of $3.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
